|
25 Sep 2019 |
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
|
|
24 Sep 2019 |
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
|
|
24 Sep 2019 |
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
|
|
23 Sep 2019 |
Mochida obtains marketing approval for teriparatide biosimilar in Japan
|
|
23 Sep 2019 |
Announcement of Receiving Manufacturing and Marketing Approval for Darbepoetin Alpha Biosimilars in Japan
|
|
22 Sep 2019 |
Once-weekly somapacitan demonstrates similar one-year height gains compared to daily somatropin in a phase 2 trial in children with growth hormone deficiency
|
|
20 Sep 2019 |
FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
|
|
19 Sep 2019 |
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
|
|
18 Sep 2019 |
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
|
18 Sep 2019 |
Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform
|
|
18 Sep 2019 |
Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels
|
|
17 Sep 2019 |
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers
|
|
17 Sep 2019 |
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
|
|
14 Sep 2019 |
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
|
|
13 Sep 2019 |
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
|
|
12 Sep 2019 |
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis
|
|
12 Sep 2019 |
Inotrem Announces €39 Million Series B Financing to Develop First-In-Class Immunology Therapeutics
|
|
10 Sep 2019 |
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia
|
|
09 Sep 2019 |
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
|
|
09 Sep 2019 |
Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration
|
|
06 Sep 2019 |
Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
|
|
03 Sep 2019 |
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
|
|
03 Sep 2019 |
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
|
|
29 Aug 2019 |
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
|
|
27 Aug 2019 |
FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea
|
